

Late-breaking poster presentations (as of 9/20/23)

Poster Session B

Friday, October 13 | 12:30 pm-4:00 pm

Level 2, Exhibit Hall D

LB_B01: *Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRAS^{G12C}(ON) inhibitor, in patients with or without prior KRAS^{G12C}(OFF) inhibitor treatment.* Pasi A. Jänne, Dana Farber Cancer Institute, Boston, MA United States.

LB_B02: *Novel PAMs from somatic mutations produce numerous pancreatic cancer-specific CRISPR-Cas9 targets for selective cell elimination: A novel gene therapy approach for cancer.* Selina Shiqing K. Teh, The Johns Hopkins University School of Medicine, Baltimore, MD United States.

LB_B03: *Lentivirus-induced ALDH1L1 knock-in inhibits proliferation and migration and activates apoptosis of human A549 lung adenocarcinoma cells.* Amira A. Abdellatef, Nutrition Research Institute, University of North Carolina at Chapel Hill, Kannapolis, NC United States.

LB_B04: *Deciphering FGFR3-TACC3 oncogenic fusions.* Julia Yemelyanenko, Netherlands Cancer Institute, Amsterdam, Netherlands.

LB_B05: *Mapping therapy resistant phenotypes in SCLC liquid biopsies with single-cell proteomics at a personalized level.* Loukia G. Karacosta, The University of Texas MD Anderson Cancer Center, Houston, TX United States.

LB_B06: *Single cell transcriptomics guided identification of antigen combinations for the design of logic-gated CAR therapies.* Sanna Madan, National Cancer Institute, Bethesda, MD United States.

LB_B07: *Probability of negative impact on adherence caused by the most frequent side effects of adjuvant endocrine therapy for premenopausal breast cancer in SOFT and TEXT Trials.* Tariq Hassan AL Qurayshah, Saudi Food and Drug Authority, Riyadh, Saudi Arabia.

LB_B08: *The SRG OncoRat supports tumors derived from several RAS mutant cell lines for pre-clinical testing of RAS-inhibitors.* Grace Walton, Hera BioLabs, Lexington, KY United States.

LB_B09: *Loss of folate enzyme ALDH1L1 promotes cancer cell proliferation and xenograft tumor growth.* Halle M. Fogle, University of North Carolina- Chapel Hill- Nutrition Department, Kannapolis, NC United States.

LB_B10: *Non-V600 BRAF mutants and their precise targeting.* Jiancheng Hu, National Cancer Centre Singapore and Duke-NUS Medical School, Singapore, Singapore.

LB_B11: *Transmembrane chloride intracellular channel 1 (tmCLIC1) protein as a key regulator of colorectal cancers' aggressiveness.* Francesca Cianci, Univerisità di Milano, Milan, Italy.

LB_B12: *Phase 2, Multicenter, Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION I).* Candace Haddox, Dana-Farber Cancer Institute, Boston, MA United States.

LB_B14: *Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors.* Jordi Rodon, MD Anderson Cancer Center, Houston, TX United States.

LB_B15: *The antiproliferative activity of metformin in glioblastoma stem cells is mediated by the direct binding and functional inhibition of the membrane configuration of CLIC1 protein.* Michele M. Mazzanti, University of Milano, Milano, Italy.

LB_B16: *Quantification of immune-oncology drug responses in autologous co-cultures of ex vivo patient tumor tissues with PBMCs.* Mariusz Madej, Crown Bioscience Netherlands, Leiden, Netherlands.

LB_B17: *Single-cell analysis of dynamic remodeling of radiated TNBC cells.* Minhee Ku, Yonsei University, Seoul, Korea, Republic of.

LB_B18: *Rapid and Reproducible Scaffold Free Organoid Formation for Personalized Medicine: Multiomic Analysis of In-Vitro Cancer Patient Model.* Ying-Chih Chang, Acrocyte Therapeutics, Taipei, Taiwan (Greater China).

LB_B19: *Utilizing genome-informed modeling to assess CDK4/6 inhibitor response in breast cancer patients, simulate clinical trials, and result in novel CDK4/6 inhibitor treatment for chordoma patients.* Jianfei Yang, Turing-Darwin Laboratory, Beijing, China (Mainland).

LB_B20: *The Unity Theory of One: The dynamic algorithm of mass action law for drug and biosimilar digital evaluation/simulation in molecules, cells, and organs, regardless of units, physical states, and mechanisms.* Ting-Chao Chou, PD Science LLC (USA), Paramus, NJ United States.

LB_B21: *Extracellular RNA signatures of mutant KRAS-driven lung cancer.* Sree lakshmi Velandi Maroli, University of California, Santa Cruz, Santa Cruz, CA United States.

LB_B22: *DrugMap: A quantitative pan-cancer analysis of cysteine ligandability.* Liron Bar-Peled, MGH/HMS, Boston, MA United States.

LB_B23: *Magnetospirillum magneticum promotes iron competition and triggers apoptosis in human cancer cells.* Stefano Menghini, ETHZ, Zurich, Switzerland.

LB_B24: *Validating novel therapeutic antibodies for targeting head & neck squamous cell malignancies.* Ameer S. Basta, USF Health Morsani College of Medicine, Tampa, FL United States.

LB_B25: *Novel strategy for RAS-pathway targeting: Initial results from a phase 1b/2 clinical trial of the oral HDAC inhibitor bocodepsin (OKI-179) combined with binimetinib in patients with RAS-pathway mutated solid tumors and NRAS-mutated melanoma.* Rodabe N. Amaria, MD Anderson Cancer Center, Houston, TX United States.

LB_B26: *Efficacy and tolerability of a novel pan-RAS inhibitor with a unique mechanism of selectivity in mouse models of pancreatic cancer.* Gary A. Piazza, Auburn University Harrison College of Pharmacy, Auburn, AL United States.